Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.45 |
| ▸ | ANPEP | P15144 | 3/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.45 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5853399 | 0.84 | IL1RN (0.38) | LAP3ANPEPRNPEPDNPEPREN | |
| SCHEMBL5619617 | 0.78 | LAP3 (0.44) | LAP3ANPEPRNPEPDNPEPCCR1 | |
| SCHEMBL6832228 | 0.76 | CCR1 (0.54) | LAP3ANPEPRNPEPDNPEPCCR1 | |
| SCHEMBL7580246 | 0.76 | CCR1 (0.54) | LAP3ANPEPRNPEPDNPEPCCR1 | |
| SCHEMBL5389179 | 0.74 | F2 (0.40) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL5389173 | 0.74 | F2 (0.40) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| Hydrochloric Acid SCHEMBL5225608 | 0.73 | F2 (0.40) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| Hydrochloric Acid SCHEMBL5225613 | 0.73 | F2 (0.40) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL7589901 | 0.71 | LAP3 (0.70) | LAP3ANPEPRNPEPDNPEPCCR1 | |
| SCHEMBL7679505 | 0.71 | LAP3 (0.70) | LAP3ANPEPRNPEPDNPEPCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160905-B2 | Hydroxyethylene compounds with Asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-17 | — | — | US | disclosed |
| EP-1448516-A1 | HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045903-A1 | HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | BACE2, BACE1, PSEN2 | LAP3 898/4885ANPEP 99/4885RNPEP 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.